

Correction: Improved Survival Outcomes in Cancer Patients with Hereditary Hemorrhagic Telangiectasia

In this article (Cancer Epidemiol Biomarkers Prev 2014;23:117–25), which appeared in the January 2014 issue of *Cancer Epidemiology, Biomarkers & Prevention* (1), a source of grant support was not included in the grant support section of the article. The modified grant support section is included below. The authors regret this error.

Grant Support

This work was supported by The National Center for Research Resources (NCRR) grant P30RR030927/P30GM103392 (R. Friesel, PI); P. Brooks was supported by National Cancer Institute (NCI) grant R01 CA91645; and C.P.H. Vary was supported by National Heart, Lung, and Blood Institute (NHLBI) grant R01 HL083151 (of the NIH). All investigators gratefully acknowledge institutional support from the Maine Medical Center. This research is supported in part through the NIH National Institute of General Medical Sciences (NIH/NIGMS) COBRE in Stem Cell Biology and Regenerative Medicine (8P20GM103465).

Reference

1. Duarte CW, Murray K, Lucas FL, Fairfield K, Miller H, Brooks P, et al. Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. *Cancer Epidemiol Biomarkers Prev* 2014;23:117–25.

Published online May 1, 2015.

doi: 10.1158/1055-9965.EPI-14-1404

©2015 American Association for Cancer Research.